Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop ...

Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera ...

Arvinas reported early-stage data for its PROTAC program in healthy volunteers, hoping the results will eventually translate ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on HilleVax, Inc (HLVX – Research Report), Lexicon ...

According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.4% and a 45.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company ...

Hudbay (TSX, NYSE: HBM) is a copper-focused critical minerals company with three long-life operations and a world-class pipeline of copper growth projects in tier-one mining jurisdictions of Canada, ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Charles Schwab Investment Management Inc. lifted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 1.0% during the 4th quarter, according to its most recent disclosure with the ...